Science Translational Medicine

Journal Information
ISSN / EISSN : 1946-6234 / 1946-6242
Former Publisher: American Association for the Advancement of Science (AAAS) (10.1126)
Total articles ≅ 5,529
Current Coverage
SCOPUS
PUBMED
MEDLINE
MEDICUS
SCIE
Archived in
SHERPA/ROMEO
Filter:

Latest articles in this journal

, , Anouk Stam, Marina Sogorb-Gonzalez, Cynthia Brouwers, Carlos Vendrell-Tornero, Seyda Acar-Broekmans, Lieke Paerels, Jiri Klima, Bozena Bohuslavova, et al.
Science Translational Medicine, Volume 13; doi:10.1126/scitranslmed.abb8920

The publisher has not yet granted permission to display this abstract.
Science Translational Medicine, Volume 13; doi:10.1126/scitranslmed.abe2967

The publisher has not yet granted permission to display this abstract.
Diana Mayor-Nunez, Zhanxin Ji, Xiujun Sun, Lucy Teves, J. David Garman,
Science Translational Medicine, Volume 13; doi:10.1126/scitranslmed.abb1498

The publisher has not yet granted permission to display this abstract.
Peiling Luan, Davide D’Amico, , Pirkka-Pekka Laurila, , , Tanes Imamura de Lima, , Chris Rinsch, Nadège Zanou, et al.
Science Translational Medicine, Volume 13; doi:10.1126/scitranslmed.abb0319

The publisher has not yet granted permission to display this abstract.
Weiqin Yang, Yu Feng, Jingying Zhou, Otto Ka-Wing Cheung, Jianquan Cao, Jing Wang, Wenshu Tang, Yalin Tu, Liangliang Xu, Feng Wu, et al.
Science Translational Medicine, Volume 13; doi:10.1126/scitranslmed.aaz6804

The publisher has not yet granted permission to display this abstract.
Cassio M. Fontes, Barbara D. Lipes, Jason Liu, Krystle N. Agans, Aiwei Yan, Patricia Shi, Daniela F. Cruz, Garrett Kelly, Kelli M. Luginbuhl, Daniel Y. Joh, et al.
Science Translational Medicine, Volume 13; doi:10.1126/scitranslmed.abd9696

The publisher has not yet granted permission to display this abstract.
Yury Kryvalap, Matthew L. Jiang, Nadzeya Kryvalap, Cole Hendrickson,
Science Translational Medicine, Volume 13; doi:10.1126/scitranslmed.abf1587

The publisher has not yet granted permission to display this abstract.
, Patricia L. Brown-Augsburger, , Kathryn Westendorf, Julian Davies, Thomas P. Cujec, Christopher M. Wiethoff, Jamie L. Blackbourne, Beverly A. Heinz, Denisa Foster, et al.
Science Translational Medicine; doi:10.1126/scitranslmed.abf1906

Abstract:
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies are a key class of therapeutics which may bridge widespread vaccination campaigns and offer a treatment solution in populations less responsive to vaccination. Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led to the identification of LY-CoV555 (also known as bamlanivimab), a potent anti-spike neutralizing antibody from a hospitalized, convalescent patient with coronavirus disease 2019 (COVID-19). Biochemical, structural, and functional characterization of LY-CoV555 revealed high-affinity binding to the receptor-binding domain, angiotensin converting enzyme 2 binding inhibition, and potent neutralizing activity. A pharmacokinetic study of LY-CoV555 conducted in cynomolgus monkeys demonstrated a mean half-life of 13 days, and clearance of 0.22 mL/hr/kg, consistent with a typical human therapeutic antibody. In a rhesus macaque challenge model, prophylactic doses as low as 2.5 mg/kg reduced viral replication in the upper and lower respiratory tract in samples collected through study Day 6 following viral inoculation. This antibody has entered clinical testing and is being evaluated across a spectrum of COVID-19 indications, including prevention and treatment.
Akira Nishio, Fabian J. Bolte, Kazuyo Takeda, Nana Park, Zu-Xi Yu, Heiyoung Park, Kristin Valdez, ,
Science Translational Medicine, Volume 13; doi:10.1126/scitranslmed.aba6322

The publisher has not yet granted permission to display this abstract.
Silvia Ribo, , Laura Martinez-Guino, Izaskun García-Mantrana, , Mireia Tondo, Erland Arning, Miquel Nofrarías, , Antonio Fernández-Pérez, et al.
Science Translational Medicine, Volume 13; doi:10.1126/scitranslmed.abb0322

The publisher has not yet granted permission to display this abstract.
Back to Top Top